Choosing Systemic Therapies for Patients with Unresectable or Metastatic CSCC
Anna C. Pavlick, DO, overviews systemic therapy options for patients with unresectable or metastatic CSCC.
Source: onclive.com
Page 3 - Performance Status News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Performance Status. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Performance Status Today - Breaking & Trending Today
Moderna, Inc.: Moderna and Merck Announce mRNA-4157 , an Investigational Individualized Neoantigen Therapy, in Combination with KEYTRUDA , Demonstrated Superior Recurrence-Free Survival in Patients with High-Risk Stage III/IV Melanoma Following Complete R
MRNA-4157 (V940) in combination with KEYTRUDA reduced the risk of recurrence or death by 44% compared to KEYTRUDA alone in stage III/IV melanoma patients with high risk of recurrence following complete
Source: finanznachrichten.de
Moderna, Inc.: Moderna and Merck Announce mRNA-4157/V940, an Investigational Personalized mRNA Cancer Vaccine, in Combination with KEYTRUDA , Met Primary Efficacy Endpoint in Phase 2b KEYNOTE-942 Trial
MRNA-4157/V940, in combination with KEYTRUDA, demonstrated a statistically significant and clinically meaningful reduction in the risk of disease recurrence or death compared to KEYTRUDA monotherapy in
Source: finanznachrichten.de
Investegate |Moderna Inc Announcements | Moderna Inc: Moderna and Merck Announce mRNA Cancer Vaccine
Investegate announcements from Moderna Inc, Moderna and Merck Announce mRNA Cancer Vaccine
Source: investegate.co.uk
Cureus | SARS-CoV-2 Antibody Seroprevalence in Patients With Cancer on Systemic Antineoplastic Treatment in the First Wave of the COVID-19 Pandemic in Portugal
At the time of the first wave of the COVID-19 pandemic, patients with cancer were considered to be at high risk of serious illness and had a higher exposure risk since they needed frequent and nondeferrable hospital visits. Serological tests were not routinely used, and seroprevalence in this population was unknown. A single-center, cross-sectional study was developed to determine the seroprevalence of anti-SARS-CoV-2 antibodies (Abs) in patients with cancer undergoing systemic antineoplastic treatment. One hundred patients were consecutively recruited in a two-week period (6th-20th May 2020)...
Source: cureus.com